Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AIM WINNERS & LOSERS: Futura Medical rises on financing transaction

4th Mar 2021 11:42

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Futura Medical, up 22% at 20.08 pence, 12-month range 7.16p-24.49p. The pharmaceutical company says it has entered into financing transactions with HT Riverwood Multi-Growth Fund which will provide the company with up to GBP2 million in cash, GBP1.5 million of which has been received.

----------

Franchise Brands, up 7.7% at 109.30p, 12-month range 81p-136.65p. Says it saw a resilient performance through lockdowns and a robust recovery in second half. For 2020, revenue increases by 12% to GBP49.3 million from GBP44.0 million in 2019 and pretax profit increases to GBP3.7 million from GBP3.3 million. Franchise Brands ups final dividend to 0.80p per share from 0.65p paid in 2019.

----------

ThinkSmart, up 6.7% at 77.9p, 12-month range 12p-91.5p. The digital payments business posts rise in interim earnings. For six months to December 31, pretax profit surges to GBP53.7 million from GBP16.0 million after financial instruments gains. ThinkSmart pays 3.4p per share special dividend and capital return in December.

----------

AIM - LOSERS

----------

MediaZest, down 16% at 0.080p, 12-month range 0.01p-0.18p. The audio-visual company says financial results for the eighteen-month period were affected substantially by the Covid-19 pandemic, with reduction in revenue particularly during the first UK lockdown. Revenue GP3.1 million, down from GBP3.3 million year before and swings to GBP478,000 pretax loss from GBP6,000 profit.

----------

Angle, down 9.7% at 79.30p, 12-month range 37.15p-98p. The liquid biopsy company says it has received response from US Food & Drug Administration after requesting clearance for its Parsortix treatment. Says FDA has indicated its review processes for non Covid-19 devices are currently slower than usual due to pandemic priorities. Notes that FDA processes are outside the company's control and it is continuing to expedite all aspects of the process which are under its control in line with previously advised timescales.

----------

By Arvind Bhunjun; [email protected]

Copyright 2021 Alliance News Limited. All Rights Reserved.


Related Shares:

MediazestAngleFutura MedicalFranchise BrandsTSL.L
FTSE 100 Latest
Value8,809.74
Change53.53